Literature DB >> 14968115

Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors.

Esra Toussaint-Smith1, David B Donner, Ann Roman.   

Abstract

Human papillomavirus (HPV) 16 is involved in causing cervical cancer. The E6 and E7 proteins of HPV 16 immortalize human keratinocytes and this is due, at least in part, to inactivation of the tumor suppressor proteins p53 and pRB. These tumor suppressor proteins also regulate the expression of pro- and antiangiogenic factors by cells. For this reason, experiments were conducted to determine whether the expression of E6 and E7 in primary keratinocytes alters the phenotype of these cells such that they express diminished levels of antiangiogenic factors and/or increased levels of proangiogenic factors. To avoid variances in experimental observations, pools of human foreskin keratinocytes from multiple sources were infected with recombinant retrovirus expressing HPV 16 E6 and E7 or control retrovirus. Gene array analysis, RT-PCR, ELISAs and Western blotting showed that in cells expressing HPV 16 E6 and E7, expression levels of two potent angiogenesis inhibitors, thrombospondin-1 and maspin, were lower compared to controls. Additionally, major angiogenesis inducers, interleukin-8 and vascular endothelial growth factor (VEGF), were increased relative to controls. VEGF can be produced as multiple splice variants, all of which are required for the formation of patent blood vessels. The expression of HPV 16 E6 and E7 in keratinocytes augmented expression of VEGF 121, 145, 165 and 189. These observations show that HPV 16 E6 and E7 alter the phenotype of primary keratinocytes, diminishing expression of inhibitors and increasing expression of inducers of angiogenesis. This altered phenotype may permit keratinocytes infected by HPV 16 to play a role in the progression of cancer by permitting tumors to acquire a blood supply permissive of growth and spread.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14968115     DOI: 10.1038/sj.onc.1207442

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  45 in total

Review 1.  Targeting angiogenesis in advanced cervical cancer.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Ther Adv Med Oncol       Date:  2014-11       Impact factor: 8.168

2.  Transforming activity of a novel mutant of HPV16 E6E7 fusion gene.

Authors:  Qiang Xie; Zhi-Xiang Zhou; Ze-Lin Li; Yi Zeng
Journal:  Virol Sin       Date:  2011-06-12       Impact factor: 4.327

Review 3.  Persistence of human papillomavirus infection: keys to malignant progression.

Authors:  Jason Bodily; Laimonis A Laimins
Journal:  Trends Microbiol       Date:  2010-11-01       Impact factor: 17.079

4.  Expression of human papillomavirus type 16 E7 is sufficient to significantly increase expression of angiogenic factors but is not sufficient to induce endothelial cell migration.

Authors:  Joanna Walker; Lucy Clare Smiley; David Ingram; Ann Roman
Journal:  Virology       Date:  2010-12-14       Impact factor: 3.616

5.  Merkel cell polyomavirus T antigens promote cell proliferation and inflammatory cytokine gene expression.

Authors:  Kathleen F Richards; Anna Guastafierro; Masahiro Shuda; Tuna Toptan; Patrick S Moore; Yuan Chang
Journal:  J Gen Virol       Date:  2015-12       Impact factor: 3.891

Review 6.  Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.

Authors:  Ramez N Eskander; Krishnansu S Tewari
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

7.  Profiling pancreatic cancer-secreted proteome using 15N amino acids and serum-free media.

Authors:  Jing Xiao; Wai-Nang Paul Lee; Yingchun Zhao; Rui Cao; Vay Liang W Go; Robert R Recker; Qi Wang; Gary Guishan Xiao
Journal:  Pancreas       Date:  2010-01       Impact factor: 3.327

8.  Hypoxia-specific stabilization of HIF-1alpha by human papillomaviruses.

Authors:  Mitsuhiro Nakamura; Jason M Bodily; Melanie Beglin; Satoru Kyo; Masaki Inoue; Laimonis A Laimins
Journal:  Virology       Date:  2009-03-24       Impact factor: 3.616

Review 9.  Clinical Trials of Antiangiogenesis Therapy in Recurrent/Persistent and Metastatic Cervical Cancer.

Authors:  Jill K Alldredge; Krishnansu S Tewari
Journal:  Oncologist       Date:  2016-03-29

10.  Large-scale analysis of protein expression changes in human keratinocytes immortalized by human papilloma virus type 16 E6 and E7 oncogenes.

Authors:  Mark A Merkley; Ellen Hildebrandt; Robert H Podolsky; Hilal Arnouk; Daron G Ferris; William S Dynan; Hubert Stöppler
Journal:  Proteome Sci       Date:  2009-08-23       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.